Dyadic International (Dyadic International) ROCE % : -125.99% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Dyadic International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dyadic International's annualized ROCE % for the quarter that ended in Dec. 2023 was -125.99%.

Dyadic International ROCE % Historical Data

The historical data trend for Dyadic International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International ROCE % Chart

Dyadic International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-23.64

-30.98

-62.01

-67.42

-95.07

Dyadic International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-73.47	-73.47	-90.99	-80.98	-125.99

Dyadic International ROCE % Calculation

Dyadic International's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.191	/	( ( (13.713 - 2.449)	+	(8.219 - 2.252) )	/ 2 )
	=	-8.191	/	( (11.264	+	5.967)	/ 2 )
	=	-8.191	/	8.6155
	=	-95.07 %

Dyadic International's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-8.672	/	( ( (9.256 - 1.457)	+	(8.219 - 2.252) )	/ 2 )
	=	-8.672	/	( ( 7.799	+	5.967 )	/ 2 )
	=	-8.672	/	6.883
	=	-125.99 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Dyadic International (NAS:DYAI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dyadic International ROCE % Related Terms

Thank you for viewing the detailed overview of Dyadic International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyadic International (Dyadic International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL, USA, 33477

Website

https://www.dyadic.com

Dyadic International Inc is a global biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Executives

Ronen Tchelet	officer: VP of Research and Bus. Dvlpmt	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb	director, 10 percent owner, officer: President, CEO & Chairman	C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton	officer: Chief Business Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996	10 percent owner	C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones	officer: Managing Dir of BD & Licensing	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst	director	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland	director	C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson	officer: Chief Financial Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok	director	KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose	director	4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson	10 percent owner	1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020